Novel Treatments & Drugs

New Immuno-Radiology Treatment Being Tested on Mesothelioma

Mesothelioma is a cancer with a bad prognosis that is primarily caused by asbestos exposure. There is no cure for mesothelioma, so people diagnosed with the disease do not have a great chance of living long past their diagnoses. Clinical trials are people’s best chance of finding a better treatment[…]

Read More »

Mesothelioma Trial Involving UV1 Cancer Vaccine and Immunotherapy

A new mesothelioma clinical trial is taking place in Oslo, Norway. The trial is looking at the UV1 cancer vaccine alongside immunotherapy. The vaccine is a peptide-based drug that activates a T-cell response, allowing the immunotherapy drugs to work better. This will be the first time that UV1 is being[…]

Read More »

Quinacrine has Anti-Cancer Effects on Mesothelioma Cells

Pleural mesothelioma is a devastating cancer of the mesothelium, which is a lining of different organs. The most common type of mesothelioma is pleural, which affects the lining of the lungs while the second most common is peritoneal, which surrounds the lining of the abdomen. New treatments are constantly being[…]

Read More »

Keytruda and Tumor Treating Fields Combination Could Soon be Used for Mesothelioma

A clinical trial being tested on lung cancer could potentially be a good treatment for people with mesothelioma. The combination of Keytruda and Tumor Treating Fields is being tested for non-small cell lung cancer. Keytruda is an immune checkpoint inhibitor that allows the immune system to find cancer cells hiding[…]

Read More »

Opdivo and Yervoy Combination Could Lengthen Aggressive Mesothelioma Sufferers’ Lives

The combination of Yervoy and Opdivo was tested on mesothelioma and the overall survival was promising.   The overall survival was 18.1 months versus 14.1 months for patients receiving just chemotherapy. This is the first time that a phase III trial had an improved survival with an immunotherapy combination in a[…]

Read More »

A New Study is Looking at the Combination of Keytruda and ONCOS-102

A new combination of two existing drugs is being tested to treat mesothelioma. Merck and Targovax, which have the drugs Keytruda (pembrolizumab), an immunotherapy drug, and ONCOS-102, a modified adenovirus, are working together in the study. They can both be used on their own alongside chemotherapy to treat mesothelioma, but[…]

Read More »

The Protein Inhibitor Tazemetostat Could Soon Treat Mesothelioma

Mesothelioma could soon be treated by tazemetostat, a new protein inhibitor. Research groups at the American Society of Clinical Oncology made presentations speaking about the effectiveness of the drug on different cancers, with one of them being mesothelioma. It was shown to be effective, and could eventually be a second-line[…]

Read More »

A Combination of Immunotherapy Drugs Could Help Mesothelioma Patients

Mesothelioma is an incurable cancer of the mesothelium resulting from asbestos exposure. Many clinical trials have been found to help patients but there is still no cure. People primarily have pleural mesothelioma where the linings of the lungs have cancer, but it can also affect the lining of the abdomen[…]

Read More »

Halofuginone Could Soon be Used to Treat Mesothelioma

Mesothelioma is a devastating cancer that primarily affects the lining of the lungs and abdomen. Once exposed to asbestos, it can take years to develop and after being diagnosed, there are not many options for patients. Since there is not a cure, clinical trials can give people hope and can[…]

Read More »

Opdivo and Yervoy Work Together to Treat Pleural Mesothelioma

Mesothelioma is an aggressive cancer with very few treatment options. Patients have a low survival rate, but there is hope with clinical trials. If a clinical trial is found to be effective, patients could live longer and could eventually be cured. Opdivo and Yervoy are two immunotherapy drugs that are[…]

Read More »